Anti‐Tumor Necrosis Factor α–Related Psoriatic Lesions in Children with Inflammatory Bowel Disease: Case Report and Systematic Literature Review

Romiti, Ricardo; Araujo, Karin Milleni; Steinwurz, Flávio; Denadai, Rafael

doi:10.1111/pde.12820

Cited by 11 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most literature to date focuses on the development of PsO secondary to treatment with antitumor necrosis factor α agents. 18 -20 We demonstrated that the risk of IBD was higher in children with PsA than in patients with PsO and no arthritis. This finding is concordant with recent work from the Netherlands that demonstrated that risk of IBD was higher in adults with PsA than in adults with PsO and no arthritis.…”

Section: Discussionmentioning

confidence: 83%

Pediatric Psoriatic Arthritis

Brandon

Manos

Xiao

et al. 2018

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

Background: Relatively little is known about the epidemiology of juvenile psoriatic arthritis (PsA), including clinical features associated with the development of arthritis among children with psoriasis and subsequent risk of inflammatory comorbidities. Objective: To identify the overall risk of arthritis among children with psoriasis and subsequent risk of inflammatory comorbidities. Methods: Using Clinformatics™ DataMart (OptumInsight, Eden Prairie, MN) de-identified US administrative claims data from 2000–2013, we identified children 0–16 years with an incident diagnosis of psoriasis or PsA using ICD-9-CM diagnostic, procedure and pharmacy billing codes. Cox proportional hazard regression was performed to assess clinical features associated with development of arthritis in children with psoriasis. Incidence rate ratios were used to compare the relative frequency of co-morbid diagnoses. Results: We identified 212 children with PsA, 4,312 with psoriasis-only, and 45,240 controls. Approximately 33% of children with PsA received a diagnostic code for psoriasis before arthritis. Median time to index code for arthritis after index code for psoriasis was 17.6 months (IQR 4.1–38.1). Older age and uveitis were associated with a significantly increased risk of developing arthritis in children with psoriasis. Children with PsA had a significantly increased risk of uveitis, diabetes, and depressive disorder when compared to patients with psoriasis and inflammatory bowel disease, uveitis, diabetes, and depressive disorder when compared to controls. Conclusion: Most children with PsA developed arthritis first. Older age and uveitis were risk factors for arthritis among children with psoriasis. PsA was associated with increased risk of several clinically relevant inflammatory comorbidities.

show abstract

Section: Discussionmentioning

confidence: 83%

Pediatric Psoriatic Arthritis

Brandon

Manos

Xiao

et al. 2018

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

show abstract

“…Making this distinction is important, because drug-induced psoriasis tends to be more resistant to therapy if the offending agent is not discontinued, and drug-aggravated psoriasis may remain chronic even with discontinuation. 4,5 Unlike in our patient, the decision to discontinue the offending drug may be more difficult in other situations. This is often the case of children with inflammatory bowel disease who develop severe psoriasis secondary to the use of anti-TNF alpha agents.…”

Section: Discussionmentioning

confidence: 64%

“…A detailed review of our patient's medications pointed to drug‐induced psoriasis rather than drug‐aggravated psoriasis, which is seen more often in patients with a positive family history and genetic predisposition to psoriasis. Making this distinction is important, because drug‐induced psoriasis tends to be more resistant to therapy if the offending agent is not discontinued, and drug‐aggravated psoriasis may remain chronic even with discontinuation . Unlike in our patient, the decision to discontinue the offending drug may be more difficult in other situations.…”

Section: Discussionmentioning

confidence: 83%

Interferon‐alpha induced psoriasis in a teenager

Mendieta

Irfan

Faith

2018

Pediatric Dermatology

View full text Add to dashboard Cite

Exacerbation of preexisting and development of new-onset psoriasis have been reported secondary to interferon treatment and, more recently, with newer biologic agents. We report a case of interferon-induced psoriasis in an adolescent with hepatitis C, a rarely reported medication reaction in children. This case highlights the importance of reviewing a patient's medication list when evaluating cutaneous disorders.

show abstract

“…TNF antagonists induce psoriasiform lesions in 4% to 10% of cases . Its pathogenesis remains poorly understood, but it is hypothesized that TNF inhibitors lead to increased production of interferon‐α, which leads to recruitment of Th17 cells in the skin through the chemokine receptor CXCR3.…”

mentioning

confidence: 99%

“…Genetic predisposition with genetic variants of interleukin 12 (IL‐12) and IL‐23 receptors is possible . Psoriasiform lesions are generally treated using a conventional psoriasis approach without needing to stop TNF antagonists, with a 60% to 90% success rate , although in severe cases, most doctors stop it. Ustekinumab has been described in a few adult cases as an alternative therapy for psoriasis and CD .…”

mentioning

confidence: 99%

Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent

Bertrand¹,

Haite²,

Carré

2017

Pediatric Dermatology

View full text Add to dashboard Cite

Ustekinumab is approved for the treatment of psoriasis in adolescents and for the treatment of moderate to severe Crohn's disease (CD) in adults, but data are lacking in pediatric CD. We report a case of severe psoriasis induced by biotherapies in an adolescent with CD that improved after switching to ustekinumab (90 mg at weeks 0, 2, and 4 and then every 8 weeks). The patient had not experienced CD relapse after 1 year of follow-up. Ustekinumab can be an alternative therapy for psoriasis induced by biotherapies when conventional treatment fails and can maintain remission of CD.

show abstract

Anti‐Tumor Necrosis Factor α–Related Psoriatic Lesions in Children with Inflammatory Bowel Disease: Case Report and Systematic Literature Review

Abstract: We report a child with Crohn's disease and infliximab-induced guttate psoriasis. We also performed a systematic literature review on this intriguing paradoxical phenomenon in children with inflammatory bowel disease.

Cited by 11 publications

References 14 publications

Pediatric Psoriatic Arthritis

Pediatric Psoriatic Arthritis

Interferon‐alpha induced psoriasis in a teenager

Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent

Contact Info

Product

Resources

About